Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 2
Sponsor overview
University of Chicago
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT03879577 | https://clinicaltrials.gov/study/NCT00406302 | https://clinicaltrials.gov/study/NCT00461344 | https://clinicaltrials.gov/study/NCT00114192 | https://clinicaltrials.gov/study/NCT02642042 | https://clinicaltrials.gov/study/NCT01803503 | https://clinicaltrials.gov/study/NCT01111058
Assets
Linked programs
- Docetaxel: Registry Stop Signal (5/5)
- Everolimus (RAD 001): Registry Stop Signal (3/5)